论文部分内容阅读
曲妥珠单抗为拮抗人上皮生长因子受体2(HER2)的单克隆抗体。TOGA是一项由24个国家的122个医疗中心共同参与的3期开放随机对照试验,该试验旨在探讨曲妥珠单抗联合化疗治疗HER2阳性的晚期胃癌或食管胃结合部腺癌的效果。研究对象为经免疫组化或荧光原位杂交基因扩增方法确定存在HER2高表达的晚期胃癌或食管胃结合部腺癌患者,最终纳入
Trastuzumab is a monoclonal antibody that antagonizes human epidermal growth factor receptor 2 (HER2). TOGA is a phase 3 open-label randomized controlled trial of 122 medical centers in 24 countries to investigate the efficacy of trastuzumab in combination with chemotherapy for advanced gastric cancer or esophageal-gastric adenocarcinoma of the HER2-positive group . The subjects were confirmed by immunohistochemistry or fluorescence in situ hybridization gene amplification method in the presence of HER2 high expression of advanced gastric cancer or esophagogastric junction adenocarcinoma patients eventually included